Article

Alimera dry eye emollient drop hits market

Alimera Sciences Inc. introduces its lubricant eye drops, Soothe Emollient, the first multi-dose, emollient-based artificial tear product for dry-eye sufferers.

Alimera Sciences Inc. introduces its lubricant eye drops, Soothe Emollient, the first multi-dose, emollient-based artificial tear product for dry-eye sufferers. The product is slated to reach U.S. retail stores by Sept. 15.

Using Restoryl, an advanced lipid restorative, Soothe re-establishes the eye's protective lipid layer to reduce tear evaporation and seal essential moisture, giving patients up to 8 hours of comfort.

Alimera Sciences licensed the artificial tear product in November 2003 from Ocular Research of Boston (ORB), a group of eye-care specialists who focus on dry eye research. The agreement combined the medical expertise of ORB with the ophthalmic commercial experience of Alimera Sciences.

"This product was inspired by and developed for dry eye patients," said Donald Korb, MD, ORB president, in a company statement. "Because Soothe restores the compromised lipid layer of patients' tears, regardless of the particular dry eye state, harmful evaporation is minimized and the ocular surface is protected.

"Thus, doctors can be confident that they are giving their patients long-lasting relief," Dr. Korb said. "After years of perfecting the formula and finding the right partner, I am excited that Soothe will be accessible to patients in such a short time."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.